IDH-Mutant Gliomas

Abstract

Isocitrate dehydrogenase (IDH) mutation is one of the most critical genomic alterations in lower grade and secondary glioblastoma patient. More than 90% of IDH mutation is located at codon R132 of IDH1 gene. IDH mutation produces oncometabolite "2-hydroxyglutarate" and induces epigenetic alteration, such as DNA global methylation and histone methylation. As a result, IDH mutation promotes early gliomagenesis. Since IDH mutation is the earliest genomic event and almost always retained during tumor progression, IDH mutation is expected as novel therapeutic target. Herein, we review the clinical characteristics of IDH-mutant gliomas, biological role of IDH mutation for gliomagenesis, and current and future therapeutic approach for IDH mutant tumors.

The Effect of Single Nucleotide Polymorphism (Snp) in Glioblastoma Multiforme

“…It leads to the production of 2-hydroxyglutarate which is an oncometabolite. This in turn induces DNA methylation called G-CIMP and histone methylation which promotes the formation of Glioblastomas [34]. Studies reveal IDH mutation in Grade II and III gliomas in more than 80% of the patients suffering from secondary GBM [35].…”

“…SNP at codon 132 in IDH1 exhibits mutations in 395G>A (R132H) substitution and at R132C. In the case of IDH2, mutations were identified at codon 172 in gliomas but with a lower mutational frequency than IDH1especially in the younger generations [34,35]. Thus, further research will help in genomic analysis to identify potential useful genomic alterations that can help in targeted therapy of GBM.…”